The Cooper Companies, Inc. COO SPX
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -1.0% CAGR over 5 years.
- Trading 27.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COO The Cooper Companies, Inc. SPX | 61.21 | 30.45 | $11.94B | - | 5.91% | 4.87% | 7.35% | -0.95% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 964.70M | 1.00B | 1.06B | 1.07B | 1.02B |
| Cost of Revenue | 304.50M | 323.20M | 368.30M | 414.30M | 328.90M |
| Gross Profit | 660.20M | 679.10M | 692.00M | 650.80M | 695.20M |
| Operating Expenses | 478.20M | 494.30M | 516.30M | 510.40M | 482.40M |
| Operating Income | 182.00M | 184.80M | 175.70M | 140.40M | 212.80M |
| EBITDA | 270.30M | 261.30M | 272.70M | 239.60M | 310.10M |
| Interest Expense | 26.00M | 24.20M | 25.40M | 24.40M | 22.40M |
| Pretax Income | 153.30M | 144.50M | 151.90M | 116.80M | 192.20M |
| Tax Provision | 49.00M | 56.80M | 53.60M | 32.20M | 61.40M |
| Net Income | 104.30M | 87.70M | 98.30M | 84.60M | 130.80M |
| Diluted EPS | 0.52 | 0.44 | 0.49 | 0.43 | 0.66 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.31B | 3.59B | 3.90B | 4.09B |
| Cost of Revenue | - | 1.17B | 1.24B | 1.30B | 1.41B |
| Gross Profit | - | 2.14B | 2.36B | 2.60B | 2.68B |
| Operating Expenses | - | 1.63B | 1.82B | 1.89B | 2.00B |
| Operating Income | - | 507.60M | 533.10M | 705.70M | 682.90M |
| EBITDA | - | 878.70M | 885.90M | 1.07B | 1.04B |
| Interest Expense | - | 57.30M | 105.30M | 114.30M | 100.00M |
| Pretax Income | - | 475.30M | 412.90M | 582.30M | 566.50M |
| Tax Provision | - | 89.50M | 118.70M | 190.00M | 191.60M |
| Net Income | - | 385.80M | 294.20M | 392.30M | 374.90M |
| Diluted EPS | - | 1.94 | 1.48 | 1.96 | 1.87 |
Compounded Sales Growth
| 5 Years: | 7.35% |
| 1 Year: | 6.20% |
Compounded Profit Growth
| 5 Years: | -0.95% |
| 1 Year: | 26.90% |
Stock Price Performance
| 1 Year: | -10.35% |
| 6 Months: | -21.74% |
| 3 Months: | -26.84% |
| 1 Month: | -0.21% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 11.49B | 11.66B | 12.32B | 12.39B |
| Current Assets | - | 1.53B | 1.70B | 1.95B | 2.11B |
| Cash & Equivalents | - | 138.20M | 120.80M | 107.60M | 110.60M |
| Inventory | - | 628.70M | 735.60M | 802.70M | 846.00M |
| Receivables | - | 557.80M | 609.70M | 717.00M | 829.00M |
| Total Liabilities | - | 4.32B | 4.11B | 4.23B | 4.16B |
| Current Liabilities | - | 1.28B | 969.00M | 1.02B | 1.11B |
| Long Term Debt | - | 2.35B | 2.52B | 2.55B | 2.46B |
| Total Debt | - | 2.76B | 2.57B | 2.58B | 2.51B |
| Total Equity | - | 7.17B | 7.55B | 8.08B | 8.24B |
| Shares Outstanding | - | 215.20M | 215.70M | 217.20M | 217.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 692.40M | 607.50M | 709.30M | 796.10M |
| Investing Cash Flow | - | -1.83B | -449.00M | -764.60M | -372.90M |
| Financing Cash Flow | - | 1.19B | -173.90M | 39.20M | -425.90M |
| Capital Expenditure | - | -242.00M | -392.50M | -421.20M | -362.40M |
| Free Cash Flow | - | 450.40M | 215.00M | 288.10M | 433.70M |
| Net Change in Cash | - | 54.90M | -15.40M | -16.10M | -2.70M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 64.7% | 65.6% | 66.6% | 65.5% |
| Operating Margin % | - | 15.3% | 14.8% | 18.1% | 16.7% |
| Net Margin % | - | 11.7% | 8.2% | 10.1% | 9.2% |
| ROE % | - | 5.4% | 3.9% | 4.9% | 4.6% |
| ROCE % | - | 5.0% | 5.0% | 6.2% | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.52% | 16.62M | $1.02B |
| 2 | Vanguard Capital Management LLC | 6.52% | 12.72M | $778.52M |
| 3 | T. Rowe Price Investment Management, Inc. | 4.64% | 9.06M | $554.57M |
| 4 | State Street Corporation | 4.49% | 8.77M | $536.71M |
| 5 | Vanguard Portfolio Management LLC | 4.47% | 8.72M | $533.83M |
| 6 | Capital World Investors | 3.80% | 7.41M | $453.87M |
| 7 | Browning West Lp | 3.58% | 6.98M | $427.22M |
| 8 | Kayne Anderson Rudnick Investment Management LLC | 3.39% | 6.62M | $405.01M |
| 9 | Price (T.Rowe) Associates Inc | 2.76% | 5.39M | $330.16M |
| 10 | Geode Capital Management, LLC | 2.72% | 5.31M | $325.12M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COO